I kliniske forsøg med pioglitazon og sulfonylurea monoterapi eller i kombination var der tegn på dosisrelateret vægtøgning, hvilket kan skyldes fedtakkumulation og i nogle tilfælde væskeophobning.
In clinical trials with pioglitazone and sulphonylurea monotherapy or in combination there was evidence of dose related weight gain, which may be due to fat accumulation and in some cases associated with fluid retention.